for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
適用於治療International Working Group (IWG) Consensus Criteria 中度風險-2 或高風險之骨髓纖維化，包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化.

Ruxolitinib is a kinase inhibitor. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. Ruxolitinib inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.

Bioavailability, oral: 95%, plasma protein binding: 97%; Metabolism: primarily via CYP3A4 in liver, into 2 active and major metabolites; Excretion: mostly as metabolites, renal : 74%, feces: 22%. 

Canadian labeling: Hypersensitivity to ruxolitinib or any component of the formulation or container; history of or current progressive multifocal leukoencephalopathy.

C; The Canadian labeling recommends avoiding use during pregnancy and that women of childbearing potential and male patients use effective contraception during therapy.

It is not known whether ruxolitinib is excreted in human milk; to avoid.

anemia, thrombocytopenia, neutropenia; bruising, dizziness, headache; Increased serum ALT, increased serum AST. 

May be administered orally with or without food.
 Recommended Starting Dose:

Baseline Platelet Count	Starting Dose
>200,000/µL	20 mg twice daily
100,000/µL to 200,000/µL	15 mg twice daily
50,000/µL to <100,000/µL	5 mg twice daily and the patients should be titrated cautiously

The maximum dose of ruxolitinib is 25 mg twice daily.
Dosing must be halted immediately if any of the following occur: 
-    Platelet counts fall below 50,000/µL;
-    ANC levels fall below 500/µL;
-    Hemoglobin cannot be maintained ≥6.5 g/dL despite the use of transfusion therapy.
If unable to ingest tablets, may administer through a nasogastric (NG) tube (≥8 Fr): Suspend 1 tablet in ~40 mL water and stir for ~10 minutes and administer (within 6 hours after dispersion) with appropriate syringe; rinse NG tube with ~75 mL water.